Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-4700 vaccine for MERS-CoV in healthy volunteers
NCT04588428Phase 2Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 3
01
Overview
A Phase 2 trial of INO-4700 in Middle East respiratory syndrome (MERS), sponsored by Inovio Pharmaceuticals, Inc.. Started Jun 2021; status: completed.
02
Drugs
INO-4700
03
Conditions
Middle East respiratory syndrome (MERS)
Beyond the preview
Go deeper on NCT04588428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588428.